Market Overview

MRM Proteomics Inc and Exactis Innovation Partner to Establish Unique Clinical Proteomics Tools for Precision Medicine

Share:

MRM Proteomics Inc. is partnering with Exactis Innovation to develop and
validate a clinical proteomic test that will provide clinicians and
scientists with the ability to identify immune signatures and tumour
mutation profiles to better match patients with the most effective
treatments. The novel diagnostic test will be the first immuno-MALDI
test to measure the activity of multiple cancer-associated proteins in
patients' tumours. This approach has the potential to transform the
selection of cancer treatments by providing direct insight into the
mechanisms of disease progression and appropriate drug targets on a
patient-by-patient basis.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180912005976/en/

"Proteomics is in a position to realize the promise of precision
medicine. Proteins are the effectors of biological processes in the
cells and the targets of most drugs. We need to look to proteins for the
next step in precision medicine" s
aid Dr. Christoph Borchers, Chief
Scientific Officer for MRM Proteomics.

MRM Proteomics will use their proprietary immunoMALDI technology to
analyze breast and colorectal tumour samples obtained through Exactis's
Personalize My Treatment patient registry. Once validated, the
clinically-applicable test will be used to characterize immune
signatures and tumour mutation profiles to screen patients for response
to immuno-oncologic cancer treatments.

An important benefit for clinicians and patients is that the innovative
response-prediction tool will enable matching of patients with the most
appropriate treatment as early as possible, which increases
the chances of survival and avoids exposure to side effects from
ineffective treatments.

"This is the core potential of precision medicine with proteomics --
the ability to more accurately determine the right treatment up front
means better outcomes for cancer patients
" said Dr. Gerald Batist,
Co-Founder and Scientific Director of Exactis Innovation and Director of
the Segal Cancer Centre at the Jewish General Hospital.

The partnership builds on recent advancements in precision medicine,
molecular assays, quantitative proteomics and proteo-genomics and serves
to advance Exactis's mission to accelerate the translation of precision
oncology into clinical care. The work also fits with MRM Proteomics's
focus on delivering high-quality proteomics technologies for research
and clinical settings.

"MRM Proteomics is excited to develop biomarker assays for important
cancer proteins with Exactis to facilitate the translation of the
patented iMALDI test to the clinic where it can benefit patients. The
proteomics field is rapidly evolving, making it possible to generate
highly accurate and reproducible quantification of important oncogenic
proteins to guide treatment. This project benefits from Exactis's access
to a large number of clinical samples and high quality clinical data and
represents a remarkable opportunity to realize the potential of
proteomics in the clinic" 
said Mr. Claude Leduc, President and
CEO of MRM Proteomics.

The validated proteomic assay is expected to lead to more effective
therapy choice with improved outcomes for cancer patients while saving
significant costs associated with the use of ineffective treatments. The
test also has value in pharmaceutical research setting by providing an
efficient way to select appropriate patient sub-populations for
precision medicine clinical trials, expediting FDA approvals, and
introducing new therapeutic options to the clinic faster.

The project showcases the strengths and opportunities for the
biotechnology sector in Quebec.

"Exactis is pleased to partner with MRM-P in this project and support
a small to medium-sized enterprise (SME) in its goals to provide
innovative molecular testing technologies that support the evolution of
precision oncology. Support of diagnostic technology development in
precision oncology that capitalizes on local expertise helps the
expansion of the biotechnology/medical technology industry in Quebec" 
said
Mr. Richard Fajzel, President and CEO of Exactis innovation.

About Exactis Innovation

Exactis Innovation (Exactis) is a Canadian not-for-profit organization
created in 2014 with funds from a public/private sector collaboration,
including the Canadian Government Business-Led Networks of Centers of
Excellence, and several pharmaceutical, biotech, not-for-profit and
research organizations. Exactis is building an integrated, agile
research network to improve cancer care for Canadians by addressing the
challenge of recruiting and matching cancer patients to clinical studies
for targeted therapies that could benefit them. At the heart of the
network is a first-of-its-kind patient registry – Personalize My
Treatment (PMT) – where patients are recruited by their cancer care
institution and agree to have detailed molecular data about their cancer
stored in a digital bio-bank and also agree to be contacted if they are
considered suitable for future clinical studies that match their cancer
characteristics. For more information, please visit www.exactis.ca.

About MRM Proteomics Inc.

MRM Proteomics Inc. (MRM Proteomics) is a Canadian biotechnology
company, founded in 2010 to commercialize cutting-edge proteomics
technologies. MRM Proteomics operates as a CRO and research partner for
clients in biotechnology and pharmaceutical industries. The company's
mission is to deliver the highest quality of precision proteomics
technologies in the form of products, services, and the development of
clinical diagnostics. As experts in mass spectrometry, their portfolio
includes offerings for protein quantitation, protein and biosimilar
structural characterization, tissue imaging, phosphoproteomics and
metabolomics as well as custom-tailored research solutions. MRM
Proteomics has also developed and launched the PeptiQuantTM Plus
line of mass spectrometry-based kits for protein quantitation and
MetaboloMetricsTM kits for metabolite quantitation.

About precision medicine & proteomics

Although cancer cases are commonly grouped together based on the
affected part of the body (e.g., brain cancer, breast cancer, liver
cancer), research increasingly demonstrates that each "type" is actually
made up of many cancer subtypes, each with a distinct molecular
signature. These molecular subtypes help to explain why one patient may
respond to a given treatment, while another patient may not. Determining
each patient's molecular subtype is therefore a critical step in
improving cancer treatment plans.

"Proteomics" is a scientific method for detailed molecular profiling, by
precisely measuring the proteins that are directly responsible for
activities occurring in the cell. To this point, molecular phenotyping
has largely relied on genetics and histology analysis of tumours. These
approaches provide useful clues about the molecular identity of the
tumour and often help in finding biomarkers that are useful for
treatment selection, but they cannot reveal current protein activity in
a cell. As the effectors of molecular processes in the cell, it is
proteins that drive disease progression and that are the targets of most
therapies. By enabling direct measurement of specific protein isoforms
and their activity, proteomics provides the most direct insight into the
mechanisms of disease progression and the most direct measurement of
drug targets. This provides proteomics with a unique advantage in
determining which therapeutics are likely to be effective for a given
tumour.

This project will use cutting-edge bioanalytical tools to precisely
measure the concentration of protein biomarkers in patient tumour
samples and examine those protein concentrations in the context of
detailed patient clinical data from Exactis's PMT platform. This will
result in the creation of a novel tool to ensure that cancer patients
are consistently matched with the most effective treatment as early as
possible, thereby improving their chances of survival and avoiding
unnecessary side effects associated with ineffective treatments.

View Comments and Join the Discussion!